Founded in 2002, Taibang Biologic Group (“Taibang”) is a leading Chinese biopharmaceutical company that provides a comprehensive range of plasma-derived products. The company's core business includes the development, manufacture and sale of plasma-derived products and other biopharmaceutical products.
As a leader in China's plasma-derived products industry, Taibang possesses leading international technology, one of the largest manufacturing capacities for plasma-derived products in Asia, and world-class R&D capabilities. The company's industry-leading product portfolio currently includes 10 plasma-derived products covering more than 20 specifications in three main categories: human albumin, human immunoglobulin, and human coagulation factors.
Taibang's non-plasma-derived products business segment covers a wide range of products including artificial dura, artificial spinal dura, artificial nerve conduits and anti-adhesion membranes for tendons.
In 2009, Taibang was listed on the Nasdaq Stock Exchange under the trading symbol “CBPO”. Over the course of its many years in operation, Taibang has become an industry-leading, international biopharmaceutical company. In April 2021, Taibang successfully completed its approximately $4.8 billion privatization with the support of several well-known investment funds.
With its mission to produce quality medicines that benefit humanity and its commitment to excellence and innovation, Taibang is focused on leveraging the latest R&D to manufacture top-notch products that set the standard for quality, safety and effectiveness.
Founded in 2002
自 2002 年成立以来，泰邦集团积极参与各种社会活动，帮助弱势群体，支持低收入患者家庭。
Taibang's Chairman and CEO Joseph Chow has over 25 years of experience in corporate finance, financial advisory and corporate management and has held senior executive and managerial positions in various well-known public and private companies.
Pang Guangli is recognized as an industry expert with over 35 years of experience in R&D, production and corporate management in China's plasma-derived products industry.
Yuan Feng has over 25 years of experience in corporate operations, finance and investment management and has held senior executive and managerial positions in various large public and private companies.
Taibang's CFO Gary Wang has over 22 years of senior management experience in finance and corporate roles in Fortune Global 500 companies and large public companies.
Sun Bing has worked for over 20 years in the medical device industry in areas including production management, marketing and corporate operations management.
Yang Gang has over 25 years of experience in China's plasma-derived products industry in the areas of R&D, production management and corporate operations management.
Xia Nan as worked for over 27 years in human resources management and has held senior HR positions in several well-known enterprises.